Population-level trends in relative survival for cervical cancer

American Journal of Obstetrics and Gynecology

Volumn 213, Issue 5, 2015, Pages 670.e1-670.e7

  Wright, Jason D ^a,c   Chen, Ling ^a   Tergas, Ana I ^a,b,c   Burke, William M ^a,c   Hou, June Y ^a,c   Neugut, Alfred I ^a,b,c   Ananth, Cande V ^a,b   Hershman, Dawn L ^a,b,c  

^a Columbia University ^*  (United States)

^b New York Presbyterian Hospital ^*  (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

cervical cancer; cervical carcinoma; relative survival; survival; trends

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; TREND STUDY; UTERINE CERVIX CANCER; CANCER REGISTRY; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SEER PROGRAM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 84946064069     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2015.07.012     Document Type: Article

References (42)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. M. Morris, P.J. Eifel, J. Lu, and et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer N Engl J Med 340 1999 1137 1143
3. H.M. Keys, B.N. Bundy, F.B. Stehman, and et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma N Engl J Med 340 1999 1154 1161
4. P.G. Rose, B.N. Bundy, E.B. Watkins, and et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer N Engl J Med 340 1999 1144 1153
5. C.W. Whitney, W. Sause, B.N. Bundy, and et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study J Clin Oncol 17 1999 1339 1348
6. L. Kachuri, P. De, L.F. Ellison, and R. Semenciw Cancer incidence, mortality and survival trends in Canada, 1970-2007 Chronic Dis Inj Can 33 2013 69 80
7. T. Chen, L. Jansen, A. Gondos, and et al. Survival of cervical cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage Acta Oncol 51 2012 915 921
8. N. Akhtar-Danesh, L. Elit, and A. Lytwyn Temporal trends in the relative survival among patients diagnosed with ovarian cancer in Canada 1992-2005: a population-based study Gynecol Oncol 123 2011 192 195
9. A. Klint, L. Tryggvadottir, F. Bray, and et al. Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964-2003 followed up to the end of 2006 Acta Oncol 49 2010 632 643
10. N. Akhtar-Danesh, L. Elit, and A. Lytwyn Temporal trends in the relative survival among women with cervical cancer in Canada: a population-based study Int J Gynecol Cancer 22 2012 1208 1213
11. H.O. Adami, J. Ponten, P. Sparen, R. Bergstrom, L. Gustafsson, and L.G. Friberg Survival trend after invasive cervical cancer diagnosis in Sweden before and after cytologic screening 1960-1984 Cancer 73 1994 140 147
12. Life expectancy, United States of America. Available at: https://www.google.com/webhp?sourceid=chrome-instant&rlz=1C5ACMJ-enUS518US558&ion=1&espv=2&ie=UTF-8-q=life%20expectancy%20in%20the%20united%20states. Accessed Oct. 12, 2014.
13. D. Yin, C.R. Morris, J.H. Bates, and R.R. German Effect of misclassified underlying cause of death on survival estimates of colon and rectal cancer J Natl Cancer Inst 103 2011 1130 1133
14. C. Percy, E. Stanek III, and L. Gloeckler Accuracy of cancer death certificates and its effect on cancer mortality statistics Am J Public Health 71 1981 242 250
15. C.M. Rutter, E.A. Johnson, E.J. Feuer, A.B. Knudsen, K.M. Kuntz, and D. Schrag Secular trends in colon and rectal cancer relative survival J Natl Cancer Inst 105 2013 1806 1813
16. S.R. Hinchliffe, M.J. Rutherford, M.J. Crowther, C.P. Nelson, and P.C. Lambert Should relative survival be used with lung cancer data? Br J Cancer 106 2012 1854 1859
17. M.A. Schonberg, E.R. Marcantonio, L. Ngo, D. Li, R.A. Silliman, and E.P. McCarthy Causes of death and relative survival of older women after a breast cancer diagnosis J Clin Oncol 29 2011 1570 1577
18. D.E. Henson, and L.A. Ries On the estimation of survival Semin Surg Oncol 10 1994 2 6
19. J.W. Gamel, and R.L. Vogel Non-parametric comparison of relative versus cause-specific survival in Surveillance, Epidemiology and End Results (SEER) program breast cancer patients Stat Methods Med Res 10 2001 339 352
20. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) program SEER∗Stat database: incidence-SEER 18 regs research data + Hurricane Katrina impacted Louisiana cases, Nov 2013 sub (1973-2011 varying)-linked to county attributes-total US, 1969-2012 counties, National Cancer Institute, DCCPS, surveillance research program, surveillance systems branch, released April 2014 (updated 5/7/2014), based on the November 2013 submission. Available at: http://www.seer.cancer.gov.) Accessed July 28, 2014.
21. F. Ederer, and H. Heise Instructions to IBM 650 programmers in processing survival computations. Technical, end results evaluation section 1959 National Cancer Institute
22. Surveillance Research Program, National Cancer Institute SEER∗Stat software version 8.1.5. Available at: http://www.seer.cancer.gov/seerstat. Accessed July 28, 2014.
23. F. Ederer, L.M. Axtell, and S.J. Cutler The relative survival rate: a statistical methodology Natl Cancer Inst Monogr 6 1961 101 121
24. J. Esteve, E. Benhamou, and L. Raymond Statistical methods in cancer research, volume IV: descriptive epidemiology IARC Sci Publ 1994 1 302
25. Estimating and modeling relative survival using SAS. Available at: http://www.pauldickman.com/survival/sas/relative-survival-using-sas.pdf. Accessed Aug. 13, 2014.
26. P.W. Dickman, A. Sloggett, M. Hills, and T. Hakulinen Regression models for relative survival Stat Med 23 2004 51 64
27. T. Hakulinen, and L. Tenkanen Regression analysis of relative survival rates J R Stat Soc Ser C Appl Stat 36 1987 309 317
28. S. Suissa Relative excess risk: an alternative measure of comparative risk Am J Epidemiol 150 1999 279 282
29. M. Bielska-Lasota, R. Inghelmann, L. van de Poll-Franse, and R. Capocaccia Trends in cervical cancer survival in Europe, 1983-1994: a population-based study Gynecol Oncol 105 2007 609 619
30. G. Gatta, R. Capocaccia, T. Hakulinen, and et al. Variations in survival for invasive cervical cancer among European women, 1978-89. EUROCARE Working Group Cancer Causes Control 10 1999 575 581
31. F. Landoni, A. Maneo, A. Colombo, and et al. Randomized study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer Lancet 350 1997 535 540
32. E.M. George, A.I. Tergas, C.V. Ananth, and et al. Safety and tolerance of radical hysterectomy for cervical cancer in the elderly Gynecol Oncol 134 2014 36 41
33. L. Spoozak, S.N. Lewin, W.M. Burke, and et al. Microinvasive adenocarcinoma of the cervix Am J Obstet Gynecol 206 2012 80.e1 80.e6
34. National Institutes of Health. NCI issues clinical announcement on cervical cancer: chemotherapy plus radiation improves survival. Available at: http://www.nih.gov/news/pr/feb99/nci-22.htm. Accessed Oct. 12, 2014.
35. H.J. Long III, B.N. Bundy, E.C. Grendys Jr., and et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study J Clin Oncol 23 2005 4626 4633
36. D.H. Moore, J.A. Blessing, R.P. McQuellon, and et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 22 2004 3113 3119
37. K.S. Tewari, M.W. Sill, H.J. Long III, and et al. Improved survival with bevacizumab in advanced cervical cancer N Engl J Med 370 2014 734 743
38. B.J. Monk, M.W. Sill, D.S. McMeekin, and et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study J Clin Oncol 27 2009 4649 4655
39. FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions N Engl J Med 356 2007 1915 1927
40. J. Paavonen, D. Jenkins, F.X. Bosch, and et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled trial Lancet 369 2007 2161 2170
41. B. Romanowski, P.C. de Borba, P.S. Naud, and et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomized placebo-controlled trial up to 6.4 years Lancet 374 2009 1975 1985
42. N. Munoz, R. Manalastas Jr., P. Pitisuttithum, and et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomized, double-blind trial Lancet 373 2009 1949 1957